Neal D. Shore, MD, FACS | Authors

Articles

The Utility of ODM-201 in CRPC

February 13, 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).